Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03052764 · ClinicalTrials.gov registry record · Phase 4
Evaluation of an Alternative Injection Paradigm for OnabotulinumtoxinA (BOTOX®) in the Treatment of Overactive Bladder in Patients With Urinary Incontinence
A Phase 4 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 4
- Development phase
- 120
- Enrollment target
NCT03052764 is a Phase 4 study that has completed, run by Allergan. The registered enrollment target is 120 participants.
The verdict
NCT03052764, a Phase 4 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 120 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy and safety of onabotulinumtoxinA 100 U (BOTOX®), compared to placebo, when injected into the bladder using an alternative injection paradigm in reducing the number of daily urinary incontinence episodes in patients with overactive bladder (OAB) and urinary incontinence whose symptoms have not been adequately managed with an anticholinergic.
Interventions
- BIOLOGICAL onabotulinumtoxinA
- DRUG Placebo (saline)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2016-12-12 |
| Est. Completion | 2018-12-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03052764
The ClinicalTrials.gov registry entry for NCT03052764 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which onabotulinumtoxinA is the first listed.
NCT03052764 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03052764 about?
NCT03052764 is a clinical study titled "Evaluation of an Alternative Injection Paradigm for OnabotulinumtoxinA (BOTOX®) in the Treatment of Overactive Bladder in Patients With Urinary Incontinence". This study will evaluate the efficacy and safety of onabotulinumtoxinA 100 U (BOTOX®), compared to placebo, when injected into the bladder using an alternative injection paradigm in reducing the number of daily urinary incontinence episodes in patients with overactive bladder (OAB) and urinary incon...
What is the current status of trial NCT03052764?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 120 participants. The study started on 2016-12-12. Estimated completion is 2018-12-10.
What interventions are being tested in trial NCT03052764?
The interventions under investigation include: onabotulinumtoxinA (BIOLOGICAL), Placebo (saline) (DRUG).
Who is sponsoring clinical trial NCT03052764?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.